Evidence map›Paper›PMID 28185568›Full record

ArticleBMC bioinformatics2016

Identification of expression patterns in the progression of disease stages by integration of transcriptomic data.

Sara Aibar, Maria Abaigar, Francisco Jose Campos-Laborie, Jose Manuel Sánchez-Santos, Jesus M Hernandez-Rivas, Javier De Las Rivas

Abstract read
In one paragraph

Article in BMC bioinformatics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sara AibarBioinformatics and Functional Genomics research group, Cancer Research Center (IMBCC, CSIC/USAL) and Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain.
Maria AbaigarUnidad de Diagnóstico Molecular y Celular del Cáncer, Cancer Research Center (IMBCC, CSIC/USAL) and Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain.
Francisco Jose Campos-LaborieBioinformatics and Functional Genomics research group, Cancer Research Center (IMBCC, CSIC/USAL) and Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain.
Jose Manuel Sánchez-SantosBioinformatics and Functional Genomics research group, Cancer Research Center (IMBCC, CSIC/USAL) and Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain.
Jesus M Hernandez-RivasUnidad de Diagnóstico Molecular y Celular del Cáncer, Cancer Research Center (IMBCC, CSIC/USAL) and Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain.
Javier De Las RivasBioinformatics and Functional Genomics research group, Cancer Research Center (IMBCC, CSIC/USAL) and Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain. jrivas@usal.es.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn the study of complex diseases using genome-wide expression data from clinical samples, a difficult case is the identification and mapping of the gene signatures associated to the stages that occur in the progression of a disease. The stages usually correspond to different subtypes or classes of the disease, and the difficulty to identify them often comes from patient heterogeneity and sample variability that can hide the biomedical relevant changes that characterize each stage, making standard differential analysis inadequate or inefficient.

resultsWe propose a methodology to study diseases or disease stages ordered in a sequential manner (e.g. from early stages with good prognosis to more acute or serious stages associated to poor prognosis). The methodology is applied to diseases that have been studied obtaining genome-wide expression profiling of cohorts of patients at different stages. The approach allows searching for consistent expression patterns along the progression of the disease through two major steps: (i) identifying genes with increasing or decreasing trends in the progression of the disease; (ii) clustering the increasing/decreasing gene expression patterns using an unsupervised approach to reveal whether there are consistent patterns and find genes altered at specific disease stages. The first step is carried out using Gamma rank correlation to identify genes whose expression correlates with a categorical variable that represents the stages of the disease. The second step is done using a Self Organizing Map (SOM) to cluster the genes according to their progressive profiles and identify specific patterns. Both steps are done after normalization of the genomic data to allow the integration of multiple independent datasets. In order to validate the results and evaluate their consistency and biological relevance, the methodology is applied to datasets of three different diseases: myelodysplastic syndrome, colorectal cancer and Alzheimer's disease. A software script written in R, named genediseasePatterns, is provided to allow the use and application of the methodology.

conclusionThe method presented allows the analysis of the progression of complex and heterogeneous diseases that can be divided in pathological stages. It identifies gene groups whose expression patterns change along the advance of the disease, and it can be applied to different types of genomic data studying cohorts of patients in different states.

Indexed as

TranscriptomeAlgorithmsAlzheimer DiseaseCluster AnalysisColorectal NeoplasmsDatabases, GeneticDisease ProgressionGene Expression ProfilingHumansMyelodysplastic SyndromesNeoplasm StagingSequence Analysis, RNASeverity of Illness IndexBioinformaticsCancerData integrationDisease progressionDisease stageDisease subtypeExpression patternExpression profilingGene expressionGene signatureLeukemiaPattern recognitionTranscriptomics

Identifiers

PMID28185568
PMCPMC5133487

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.